Oculis Raises CHF20 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases

New Investors include Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners

LAUSANNE, Switzerland, January 4, 2018 -- (Healthcare Sales & Marketing Network) -- Oculis (www.oculis.com), a clinical-stage biotechnology company focused on... Biopharmaceuticals, Ophthalmology, Venture Capital Oculis , Diabetic Macular Edema

Source: HSMN NewsFeed - January 4, 2018 Category: Pharmaceuticals Source Type: news